BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Conway EM, Pryzdial ELG. Is the COVID-19 thrombotic catastrophe complement-connected? J Thromb Haemost 2020;18:2812-22. [PMID: 32762081 DOI: 10.1111/jth.15050] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Shi H, Zuo Y, Navaz S, Harbaugh A, Hoy C, Gandhi AA, Sule G, Yalavarthi S, Gockman K, Madison JA, Wang J, Zuo M, Shi Y, Maile MD, Knight JS, Kanthi Y. Endothelial cell-activating antibodies in COVID-19. medRxiv 2021:2021. [PMID: 33501469 DOI: 10.1101/2021.01.18.21250041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
2 Steadman E, Fandaros M, Yin W. SARS-CoV-2 and Plasma Hypercoagulability. Cell Mol Bioeng 2021;:1-10. [PMID: 34221178 DOI: 10.1007/s12195-021-00685-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Van Quekelberghe C, Latta K, Kunzmann S, Grohmann M, Hansen M. Atypical hemolytic uremic syndrome induced by SARS-CoV2 infection in infants with EXOSC3 mutation. Pediatr Nephrol 2022. [PMID: 35522339 DOI: 10.1007/s00467-022-05566-6] [Reference Citation Analysis]
4 Macor P, Durigutto P, Mangogna A, Bussani R, De Maso L, D'Errico S, Zanon M, Pozzi N, Meroni PL, Tedesco F. Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients. Biomedicines 2021;9:1003. [PMID: 34440207 DOI: 10.3390/biomedicines9081003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Fernandes M, Brábek J. COVID-19, corticosteroids and public health: a reappraisal. Public Health 2021;197:48-55. [PMID: 34325124 DOI: 10.1016/j.puhe.2021.05.028] [Reference Citation Analysis]
6 Leatherdale A, Stukas S, Lei V, West HE, Campbell CJ, Hoiland RL, Cooper J, Wellington CL, Sekhon MS, Pryzdial ELG, Conway EM. Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality. Med Microbiol Immunol 2022. [PMID: 35034207 DOI: 10.1007/s00430-021-00725-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Plášek J, Gumulec J, Máca J, Škarda J, Procházka V, Grézl T, Václavík J. COVID-19 Associated Coagulopathy: Mechanisms and Host-Directed Treatment. Am J Med Sci 2021:S0002-9629(21)00403-1. [PMID: 34752741 DOI: 10.1016/j.amjms.2021.10.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Morrow AJ, Sykes R, McIntosh A, Kamdar A, Bagot C, Bayes HK, Blyth KG, Briscoe M, Bulluck H, Carrick D, Church C, Corcoran D, Findlay I, Gibson VB, Gillespie L, Grieve D, Hall Barrientos P, Ho A, Lang NN, Lennie V, Lowe DJ, Macfarlane PW, Mark PB, Mayne KJ, McConnachie A, McGeoch R, McGinley C, McKee C, Nordin S, Payne A, Rankin AJ, Robertson KE, Roditi G, Ryan N, Sattar N, Allwood-Spiers S, Stobo D, Touyz RM, Veldtman G, Watkins S, Weeden S, Weir RA, Welsh P, Wereski R, Mangion K, Berry C; CISCO-19 Consortium. A multisystem, cardio-renal investigation of post-COVID-19 illness. Nat Med 2022. [PMID: 35606551 DOI: 10.1038/s41591-022-01837-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Khandelwal G, Ray A, Sethi S, Harikrishnan HK, Khandelwal C, Sadasivam B. COVID-19 and thrombotic complications-the role of anticoagulants, antiplatelets and thrombolytics. J Family Med Prim Care 2021;10:3561-7. [PMID: 34934647 DOI: 10.4103/jfmpc.jfmpc_1297_20] [Reference Citation Analysis]
10 Raina R, Vijayvargiya N, Khooblall A, Melachuri M, Deshpande S, Sharma D, Mathur K, Arora M, Sethi SK, Sandhu S. Pediatric Atypical Hemolytic Uremic Syndrome Advances. Cells 2021;10:3580. [PMID: 34944087 DOI: 10.3390/cells10123580] [Reference Citation Analysis]
11 Villar M, Urra JM, Rodríguez-Del-Río FJ, Artigas-Jerónimo S, Jiménez-Collados N, Ferreras-Colino E, Contreras M, de Mera IGF, Estrada-Peña A, Gortázar C, de la Fuente J. Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology. Front Immunol 2021;12:730710. [PMID: 34566994 DOI: 10.3389/fimmu.2021.730710] [Reference Citation Analysis]
12 Mahboubi Mehrabani M, Karvandi MS, Maafi P, Doroudian M. Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches. Rev Med Virol 2022;:e2334. [PMID: 35138001 DOI: 10.1002/rmv.2334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
14 Giryes S, Bragazzi NL, Bridgewood C, De Marco G, McGonagle D. COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells. Semin Immunopathol 2022. [PMID: 35412072 DOI: 10.1007/s00281-022-00928-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Chakir M, El Jamili M, Boudhar Z, El Hattaoui M. Simultaneous acute myocardial infarction, bilateral pulmonary embolism, and acute ischaemic cerebral stroke, a delayed complication in a patient with COVID-19 infection: case report. Eur Heart J Case Rep 2021;5:ytab218. [PMID: 34189400 DOI: 10.1093/ehjcr/ytab218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Manolis AS, Manolis TA, Manolis AA, Papatheou D, Melita H. COVID-19 Infection: Viral Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management. J Cardiovasc Pharmacol Ther 2021;26:12-24. [PMID: 32924567 DOI: 10.1177/1074248420958973] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
17 Wang H, Liu M. Complement C4, Infections, and Autoimmune Diseases. Front Immunol 2021;12:694928. [PMID: 34335607 DOI: 10.3389/fimmu.2021.694928] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
18 Quek E, Tahir H, Kumar P, Hastings R, Jha R. Treatment of COVID-19: a review of current and prospective pharmacotherapies. Br J Hosp Med (Lond) 2021;82:1-9. [PMID: 33792391 DOI: 10.12968/hmed.2021.0112] [Reference Citation Analysis]
19 Kozma GT, Mészáros T, Bakos T, Hennies M, Bencze D, Uzonyi B, Győrffy B, Cedrone E, Dobrovolskaia MA, Józsi M, Szebeni J. Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm. Front Immunol 2021;12:642860. [PMID: 33995361 DOI: 10.3389/fimmu.2021.642860] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Tatar E, Erdi ZC, Ozgur O, Tasdemir A, Tatar B. Importance of eculizumab treatment in recurrence of atypical hemolytic uremic syndrome during the SARS-CoV-2 pandemic. Int Urol Nephrol 2021. [PMID: 34003430 DOI: 10.1007/s11255-021-02890-y] [Reference Citation Analysis]
21 Tan DX, Hardeland R. Targeting Host Defense System and Rescuing Compromised Mitochondria to Increase Tolerance against Pathogens by Melatonin May Impact Outcome of Deadly Virus Infection Pertinent to COVID-19. Molecules 2020;25:E4410. [PMID: 32992875 DOI: 10.3390/molecules25194410] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
22 Vavougios GD, Ntoskas KT, Doskas TK. Impairment in selenocysteine synthesis as a candidate mechanism of inducible coagulopathy in COVID-19 patients. Med Hypotheses 2021;147:110475. [PMID: 33421689 DOI: 10.1016/j.mehy.2020.110475] [Reference Citation Analysis]
23 Medjeral-Thomas NR, Troldborg A, Hansen AG, Gisby J, Clarke CL, Prendecki M, McAdoo SP, Sandhu E, Lightstone L, Thomas DC, Willicombe M, Botto M, Peters JE, Pickering MC, Thiel S. Plasma Lectin Pathway Complement Proteins in Patients With COVID-19 and Renal Disease. Front Immunol 2021;12:671052. [PMID: 33995410 DOI: 10.3389/fimmu.2021.671052] [Reference Citation Analysis]
24 Gerber GF, Yuan X, Yu J, Cher BAY, Braunstein EM, Chaturvedi S, Brodsky RA. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria. Blood 2021;137:3670-3. [PMID: 33945618 DOI: 10.1182/blood.2021011548] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
25 Magro C, Nuovo G, Mulvey JJ, Laurence J, Harp J, Crowson AN. The skin as a critical window in unveiling the pathophysiologic principles of COVID-19. Clinics in Dermatology 2021;39:934-65. [DOI: 10.1016/j.clindermatol.2021.07.001] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Subramaniam S, Ruf W, Bosmann M. Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019. Br J Pharmacol 2021. [PMID: 34235728 DOI: 10.1111/bph.15587] [Reference Citation Analysis]
27 Ng N, Powell CA. Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease. J Clin Med 2021;10:2188. [PMID: 34069355 DOI: 10.3390/jcm10102188] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Brain D, Plant-Hately A, Heaton B, Arshad U, David C, Hedrich C, Owen A, Liptrott NJ. Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. Adv Drug Deliv Rev 2021;178:113848. [PMID: 34182016 DOI: 10.1016/j.addr.2021.113848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
29 Niederreiter J, Eck C, Ries T, Hartmann A, Märkl B, Büttner-Herold M, Amann K, Daniel C. Complement Activation via the Lectin and Alternative Pathway in Patients With Severe COVID-19. Front Immunol 2022;13:835156. [PMID: 35237273 DOI: 10.3389/fimmu.2022.835156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Kakavand H, Ariannejad H, Connors JM, Hunt BJ, Berger JS, Van Tassell BW, Middeldorp S, Piazza G, Weitz JI, Cushman M, Lip GYH, Goldhaber SZ, Bikdeli B. Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. J Thromb Haemost 2021. [PMID: 34538017 DOI: 10.1111/jth.15533] [Reference Citation Analysis]
31 Macor P, Durigutto P, Mangogna A, Bussani R, D'Errico S, Zanon M, Pozzi N, Meroni P, Tedesco F. Multi-organ complement deposition in COVID-19 patients. medRxiv 2021:2021. [PMID: 33442701 DOI: 10.1101/2021.01.07.21249116] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]